| Key Ingredients |
Glucosamine, Chondroitin Sulphate, MSM, Collagen Peptide, Boswellia (3% AKBA) |
Green-Lipped Mussel Powder, Boswellia (30% AKBA), + Synovium-supportive coactives |
| Focus of Action |
Cartilage structure support. |
Synovial inflammation modulation, resolution of root cause |
| Primary Mechanism |
Provides building blocks for cartilage; mild to nil anti-inflammatory effects |
Targets synovial macrophages, inhibits 5-LOX, restores synovial fluid production |
| AKBA Content (Boswellia) |
3% AKBA (low potency, limited effect on synovitis) |
30% AKBA (high potency; blocks leukotriene synthesis at synovial site) |
| Effect on Synovial Fluid |
Indirect or none |
Direct stimulation of synovial secretion (lubricin, HA, nutrients) |
| Omega-3 Content |
Absent |
Present in Green-Lipped Mussel (ETA, DHA, EPA) — natural inflammation resolvers |
| Onset of Action |
Mild effect in 8 to 12 weeks |
Strong, noticeable and measurable effect, often within 4 to 6 weeks |
| Inflammatory Marker Modulation |
Weak inhibition of COX-2 and TNF-α |
Strong inhibition of IL-1β, TNF-α, and MMPs; promotes pro-resolving mediators |
| Effect on Synovium Thickness & Pain |
Minimal |
Proven impact on reducing synovial hypertrophy and joint pain |
| Pain Relief Mechanism |
Mechanical cushioning via collagen & GAGs |
Neuro-inflammatory resolution; reduction in nociceptive signalling from inflamed synovium |
| Evidence Base |
Older clinical trials, mostly symptom-focused |
Supported by modern imaging studies (MRI, ultrasound) linking synovitis to OA |
| Regenerative Potential |
Mild Structural support only |
Regenerative + anti-inflammatory + pro-resolving |
| Formulation Philosophy |
Structural maintenance of joint |
Root-cause targeting of immune dys-regulation and synovial dysfunction |
